To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Artemis Announces Collaboration Agreement with Bristol-Myers
Artemis Pharmaceuticals GmbH has announced that it has signed a target validation collaboration agreement with Bristol-Myers Squibb Company.
Under the agreement Artemis will generate various genetically-engineered murine models carrying selected genetic mutations.
Bristol-Myers Squibb will use these models in its drug discovery research activities for the validation of drug screening targets.
Such targets are used to identify compounds and therapies for the treatment of diseases for various indications in humans.
The generation of the in vivo rodent models will be based on Artemis' proprietary ArteMice™ and ArteMice™ Conditional™ technologies.
These technologies are designed to enable the introduction of genetic sequences containing the CreER gene switch for conditional gene knock out and the creation of humanized conditional mutants in which murine genes are replaced by their human orthologues.
Quality control and transfer will be done together with Artemis' strategic partner company Taconic, which also provides use licenses to Bristol-Myers Squibb covering the U.S. territory for mouse models generated by Artemis, using techniques included in the PNS and Isogenic DNA patents.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
